Danis N, Comlekci A, Yener S, Durak M, Calan M, Solmaz D, Yalcin M M, Gulcu A, Demir T, Bayraktar F, Canda T
Karabuk University School of Medicine, Department of Internal Medicine, Division of Gastroenterology, Karabuk, Turkey.
"Dokuz Eylül" University School of Medicine, Department of Internal Medicine, Division of Endocrinology, Izmir, Turkey.
Acta Endocrinol (Buchar). 2022 Jan-Mar;18(1):74-78. doi: 10.4183/aeb.2022.74.
To investigate the association between papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT).
This study is a retrospective study that conducted during 7 consecutive years with a median 119.5 months follow-up.
Patients who underwent thyroidectomy in Dokuz Eylül University Hospital during 7 consecutive years were included. Patients' demographics, biochemical, radiological, and pathological results were retrospectively assessed.
Four hundred sixty nine patients were evaluated. Among 469 patients who underwent thyroidectomy, 132 (28.1%) were malignant, while 182 patients were diagnosed with HT (38.8%). PTC was ranked first at 92.4% (n: 122). The prevalence of HT was 54.9% in patients with PTC and 33.1% in patients without PTC diagnosis (p<0.001). Younger age and the presence of HT were independently associated with PTC. The presence of HT was associated with increased risk of development of PTC (OR: 2.2, %95 CI: 1.4-3.5, p<0.001) but not with TNM stage or recurrence. Lymph node metastasis at presentation was the strongest predictor of recurrence (OR: 13.9, CI: 3.5-54.6, p<0.001).
HT was an independent risk factor for development of PTC. According to our findings, HT patients (particularly with nodular HT) should be observed carefully and thyroid fine needle aspiration biopsy (TFNAB) should be encouraged if necessary.
探讨甲状腺乳头状癌(PTC)与桥本甲状腺炎(HT)之间的关联。
本研究为回顾性研究,连续进行7年,中位随访时间为119.5个月。
纳入连续7年在多库兹艾吕尔大学医院接受甲状腺切除术的患者。对患者的人口统计学、生化、放射学和病理结果进行回顾性评估。
共评估了469例患者。在469例行甲状腺切除术的患者中,132例(28.1%)为恶性,182例被诊断为HT(38.8%)。PTC占92.4%(n = 122),位居首位。PTC患者中HT的患病率为54.9%,未诊断为PTC的患者中HT患病率为33.1%(p<0.001)。年轻和HT的存在与PTC独立相关。HT的存在与PTC发生风险增加相关(OR:2.2,95%CI:1.4 - 3.5,p<0.001),但与TNM分期或复发无关。就诊时出现淋巴结转移是复发的最强预测因素(OR:13.9,CI:3.5 - 54.6,p<0.001)。
HT是PTC发生的独立危险因素。根据我们的研究结果,HT患者(尤其是结节性HT患者)应仔细观察,必要时应鼓励进行甲状腺细针穿刺活检(TFNAB)。